ČEŠKOVÁ, Eva, M. ŠEDOVÁ, R. KELLNEROVA a Olga STAROBOVÁ. Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice. PHARMACOLOGY. BASEL: KARGER, roč. 102, 3-4, s. 206-212. ISSN 0031-7012. doi:10.1159/000492079. 2018.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice
Autoři ČEŠKOVÁ, Eva (203 Česká republika, garant, domácí), M. ŠEDOVÁ (203 Česká republika), R. KELLNEROVA (203 Česká republika) a Olga STAROBOVÁ (203 Česká republika, domácí).
Vydání PHARMACOLOGY, BASEL, KARGER, 2018, 0031-7012.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30104 Pharmacology and pharmacy
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 1.615
Kód RIV RIV/00216224:14740/18:00104336
Organizační jednotka Středoevropský technologický institut
Doi http://dx.doi.org/10.1159/000492079
UT WoS 000444753700012
Klíčová slova anglicky Trazodone; Depression; Clinical practice; Treatment-resistant depression; Individualized treatment; Multimodal antidepressant
Štítky 14119612, podil, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Pavla Foltynová, Ph.D., učo 106624. Změněno: 13. 3. 2019 11:29.
Anotace
Objective: The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong (R) 300 mg) in patients with moderate to severe depression in routine clinical practice. Methods: Men and women >= 18 years old with Montgomery-Asberg Depression Rating Scale (MADRS) scores >21 and Clinical Global Impression - Severity (CGI/S) >= 4 were included in this post-authorization, non-interventional, observational prospective safety study, conducted in 8 psychiatric centers in the Czech Republic. The acute treatment phase lasted 5 weeks: 1 week of titration and 4 weeks of full-dose treatment. Patients had follow-up visits 9 and 21 weeks after commencing treatment. Results: Overall, 85 patients were enrolled in the study, of which 80 completed the acute treatment of 5 weeks. There were significant decreases in the overall MADRS score from the baseline mean value of 27.4-21.2 at week 1 (p < 0.001), and a further decrease to 7.9 at week 5 (p < 0.001). The severity of depression according to CGI/S gradually declined. Most patients reported improvement after 6 days of trazodone treatment. The most frequent adverse drug reactions (ADRs) reported were somnolence and fatigue. Conclusions: Trazodone, in the new extended-release formulation, had very good effects in clinical practice, both in previously untreated depressive episodes and in episodes not responsive to previous antidepressive therapy. (C) 2018 S. Karger AG, Basel
VytisknoutZobrazeno: 29. 3. 2024 01:18